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KEY POINTS SUMMARY  
 Over 15 million babies are born prematurely each year with approximately 1 million of 
these babies dying as a direct result of preterm delivery. 
 β2-adrenoreceptor agonists that act via cAMP can reduce uterine contractions to delay 
preterm labour, but their ability to repress uterine contractions lasts ≤ 48 hours and their 
use does not improve neonatal outcomes.  
 Previous research has suggested that cAMP inhibits myometrial contractions via protein 
kinase A (PKA) activation, but this has yet to be demonstrated with PKA-specific 
agonists.    
 We investigated the role of PKA in mediating cAMP-induced human myometrial 
relaxation, and the impact of prolonged cAMP elevation on myometrial contractility.   
 Our findings suggest that PKA is not the sole mediator of cAMP-induced myometrial 
relaxation and that prolonged prophylactic elevation of cAMP alone is unlikely to 
prevent preterm labour (PTL).   
 
 
ABSTRACT 
Acute cAMP elevation inhibits myometrial contractility, but the mechanisms responsible are 
not fully defined and the long-term effects uncertain. These need to be defined in pregnant 
human myometrium before the therapeutic potential of cAMP-elevating agents in the 
prevention of preterm labour can be realised. In the present study, we tested the hypotheses 
that PKA activity is necessary for cAMP-induced myometrial relaxation and prolonged 
cAMP elevation can prevent myometrial contractions. Myometrial tissues obtained from 
term, pre-labour elective Caesarean sections were exposed to receptor-independent cAMP 
agonists to determine the relationship between myometrial contractility (spontaneous and 
oxytocin-induced), PKA activity, HSP20 phosphorylation and expression of contraction-
associated and cAMP signalling proteins. Acute (1 h) application of cAMP agonists 
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promoted myometrial relaxation but this was weakly related to PKA activation. PKA-specific 
activator, 6-Bnz-cAMP, increased PKA activity (6.8 ± 2.0 mean fold versus vehicle; p = 
0.0313) without inducing myometrial relaxation. Spontaneous myometrial contractility 
declined after 24 hours but was less marked when tissues were constantly exposed to cAMP 
agonists, especially for 8-bromo-cAMP (4.3 ± 1.2 mean fold versus vehicle; p = 0.0043); this 
was associated with changes to calponin, cofilin and HSP20 phosphorylated/total protein 
levels. Oxytocin-induced contractions were unaffected by pre-incubation with cAMP agonists 
despite treatments being able to enhance PKA activity and HSP20 phosphorylation. These 
data suggest that cAMP-induced myometrial relaxation is not solely dependent on PKA 
activity and the ability of cAMP agonists to repress myometrial contractility is lost with 
prolonged exposure. We conclude that cAMP agonist treatment alone may not prevent 
preterm labour.   
 
ABBREVIATIONS. 6-Bnz-cAMP, N6-Benzoyladenosine-cAMP; A-kinase anchoring 
protein, AKAP; adenylate cyclase, AC; BSA, bovine serum albumin; COX-2, 
cyclooxygenase-2; Cx43, connexin-43; db-cAMP, dibutyryl cAMP; DMEM, Dulbecco’s 
Modified Eagle’s Medium; DPBS, Dulbecco’s PBS; ECL, enhanced chemiluminescence; 
EIA, enzyme immunoassay; EP, PGE2 receptor (protein); EPAC, exchange protein directly 
activated by cAMP; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GαS, G protein 
αS; HSP20, heat shock protein 20; KPSS, high potassium (60 mM KCl) physiological saline 
solution; LDS, lithium dodecyl sulphate; LTCC, L-type calcium channel; MIT, mean integral 
tension (area under the curve analysis); MLC20, myosin light chain 20; MYLP, myosin light 
chain phosphatase; OTR, oxytocin receptor; PDE, phosphodiesterase; PF 04418948, 1-(4-
Fluorobenzoyl)-3-[[(6-methoxy-2-naphthalenyl)oxy]methyl]-3-azetidinecarboxylic acid; 
PGFS, PGF synthase; PKA, protein kinase A; PSS, physiological saline solution; PTGER, 
PGE2 receptor (mRNA); PTGES, PGE synthase; PTGFR, PGF2α receptor; PTL, preterm 
labour; PVDF, polyvinylidene fluoride; qPCR, quantitative PCR; RIIα, regulatory subunit 
RIIα; SERCA2, sarco/endo-plasmic reticulum calcium ATPase 2; SM-MHC, smooth muscle 
myosin heavy chain; TTBS, Tween-Tris-buffered saline.   
 
INTRODUCTION 
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Over 15 million preterm births (≤ 37 weeks gestation) occur worldwide annually, with many 
resulting in neonatal death or life-long disability (March of Dimes, 2012). Preterm labour 
(PTL) is responsible for many of these premature births, and although acute tocolytic 
treatments can delay delivery they do not improve neonatal outcomes. Agents that increase 
intracellular cAMP content (hereon referred to as ‘cAMP agonists’) can inhibit myometrial 
contractions acutely. Indeed, β2-adrenergic agonists, which work by increasing cAMP 
synthesis, were the mainstay of PTL therapy, but proved to be ineffective with long-term 
administration and are associated with life-threatening side effects. The short duration of β2-
agonist efficacy has been attributed to β2-adrenoreceptor desensitisation, caused by a decline 
in receptor number (Michel et al., 1989) and/or G protein uncoupling (Frambach et al., 
2005). However, interest persists in the use of drugs that increase cAMP to inhibit 
myometrial contractions (Mehats et al., 2000; Croci et al., 2007; Verli et al., 2013) since this 
approach is successful in the management of other conditions associated with smooth muscle 
hyper-contractility, including asthma and pulmonary hypertension (Morgado et al., 2012; 
Billington et al., 2013). The focus has shifted to drugs that enhance cAMP levels 
independently of β2-adrenoreceptor activation, such as cAMP-phosphodiesterase (cAMP-
PDE) inhibitors (Mehats et al., 2000; Verli et al., 2013), as alternatives.  
A body of evidence exists to support a role for cAMP in maintaining uterine quiescence 
during pregnancy (Yuan & Lopez Bernal, 2007). Many endogenous pro-pregnancy hormones 
increase cAMP levels; namely relaxin, human chorionic gonadotropin and calcitonin gene-
related peptide. Key components that promote myometrial cAMP signalling are reduced upon 
labour onset, such as protein kinase A (PKA) regulatory subunit RIIα (MacDougall et al., 
2003), G protein αS (GαS; (Europe-Finner et al., 1994)) and heat shock protein 20 (HSP20, a 
PKA substrate; (Chan et al., 2014)). The last of these, HSP20, has been used to demonstrate 
the importance of PKA-driven phosphorylation in promoting smooth muscle relaxation not 
only in the myometrium (Tyson et al., 2008; Karolczak-Bayatti et al., 2011), but also in the 
myocardium (Edwards et al., 2012) and airway smooth muscle (Gerthoffer et al., 2013). 
Additionally, myometrial levels of cAMP-specific phosphodiesterase 4 (PDE4) isoform B 
increase with preterm labour (Verli et al., 2013). PKA has also been suggested to promote 
relaxation by repressing both intracellular calcium mobilisation, via inhibition of 
phosphatidylinositol turnover (Dodge & Sanborn, 1998), and myosin light chain 20 (MLC20) 
phosphorylation, by repressing Rho signalling (Murthy et al., 2003). These data, taken with 
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the ability of cAMP to acutely inhibit contractility, suggest that promoting myometrial cAMP 
signalling via PKA activation might be an effective approach to PTL prevention.  
However, a previous publication suggested that maintaining relatively elevated levels of 
myometrial PKA activity, via prostacyclin administration, enhanced oxytocin-induced 
contractions by promoting expression of contractile apparatus proteins (Fetalvero et al., 
2008). Further, the exact role played by PKA in cAMP-induced myometrial relaxation is 
uncertain and recent data suggest that other cAMP effectors may be involved in smooth 
muscle relaxation (Roscioni et al., 2011b).  
In the present study, we investigated the role of PKA in acute cAMP-induced myometrial 
relaxation and assessed the impact of prolonged cAMP elevation on myometrial contractility. 
We tested the hypotheses that (i) acute cAMP-induced relaxation is directly proportional to 
total PKA activity; (ii) PKA activation alone can induce relaxation; and (iii) prolonged 
elevation of cAMP inhibits spontaneous and oxytocin-induced contractility. 
 
MATERIALS AND METHODS 
Ethical approval & tissue collection.  
Myometrial biopsies from non-labouring pregnant women undergoing low-risk elective 
Caesarean section for term singleton pregnancies (37 + 5 to 41 + 4 weeks gestation; n = 87; 
Table 1) were collected in accordance with the Declaration of Helsinki guidelines, and with 
approval from the local research ethics committees for Guy’s & St Thomas’ Hospital (Ethics 
No. EC00/137) and Chelsea & Westminster Hospital (Ethics No. 10/H0801/45), London. 
Informed written consent was obtained from all women who participated. Biopsies were 
excised from the upper margin of incision made in the lower segment of the uterus and 
promptly immersed into sterile Dulbecco’s PBS (DPBS) for storage at 2-4oC until dissection 
for use within the same day.  
 
Materials & reagents. 
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8-bromo-cAMP, dibutyryl cAMP (db-cAMP), forskolin and rolipram were purchased from 
Sigma-Aldrich (Dorset, UK). N
6
-Benzoyladenosine-cAMP (6-Bnz-cAMP) was from Biolog 
(Bremen, Germany). Bay K8644 and 1-(4-Fluorobenzoyl)-3-[[(6-methoxy-2-
naphthalenyl)oxy]methyl]-3-azetidinecarboxylic acid (PF 04418948) were from Tocris 
Bioscience (Bristol, UK). Syntocinon® was from Alliance Pharmaceuticals (Wiltshire, UK). 
Dulbecco’s Modified Eagle’s Medium (DMEM) and DPBS were from Sigma-Aldrich. 
Materials and reagents for SDS-PAGE and western blotting were from Life Technologies 
(Paisley, UK), Bio-Rad (Hertfordshire, UK) and Millipore (Hertfordshire, UK). Suppliers of 
primary antibodies are summarised in Table 2. All secondary antibodies were from New 
England BioLabs (Hertfordshire, UK). Primers were from Life Technologies. Suppliers of 
kits are stated elsewhere in the text. All other reagents were from Sigma-Aldrich, Merck 
Chemicals (Nottingham, UK) and Fisher Scientific (Loughborough, UK).  
 
Isometric tension recording & data analysis for 1 hour acute response to cAMP 
agonists. 
Isometric tension measurements were made using an 8-channel or 4-channel (Panlab; 
Barcelona, Spain) organ bath connected to ML870 PowerLab with MLT0201 transducers or 
4SP PowerLab with MLT0210/D transducers (ADInstruments, Oxford, UK) respectively; 
samples subjected to identical experimental treatment protocols had their contractility output 
measured using the same organ bath apparatus. Longitudinal myometrial tissue strips used for 
assessing 1 hour ‘acute’ cAMP agonist treatment effects were dissected from biopsies in ice-
cold DPBS and mounted into physiological saline solution (PSS, pH 7.4; composed of 119 
mM NaCl, 4.7 mM KCl, 1.17 mM MaSO4, 1.18 mM KH2PO4, 25 µM EDTA, 25 mM 
NaHCO3, 6 mM glucose and 1.6 mM CaCl2), maintained at 37
o
C with 95 % O2/5 % CO2 
aeration in organ bath chambers.  Tension (29.4 mN) was applied to all tissues and PSS 
changed once every hour. After 1-1.5 hours of regular spontaneous contractions with a stable 
basal tension, cAMP agonist or vehicle (equivalent volume) was added with fresh PSS and 
incubated for 1 hour. Tissues were not used if they had not established stable contractions 
within 3 hours after applying tension. Each tissue strip treated with a cAMP agonist was 
paired with a vehicle-treated strip from the same biopsy.   
  
 
This article is protected by copyright. All rights reserved. 
7 
 
At the end of treatment, PSS was changed to high potassium PSS (KPSS, pH 7.4; same 
composition as PSS except for concentrations of NaCl, 63.7 mM, and KCl, 60 mM) to induce 
maximal contractile response and confirm tissue viability. After 10 minutes, KPSS was 
replaced with PSS. After a further 10 minutes, tissues were cut off from their tied ends and 
into segments, which were weighed, snap frozen in liquid nitrogen and stored at -80
o
C. All 
contractility data was analysed using LabChart 6 software (ADInstruments) to calculate mean 
integral tension values (MIT; area under the curve analysis for the sum of integrals for all 
contractions within the time period of interest, which was divided by its duration and mean 
cross-sectional area, the latter calculated from tissue strip mass and length (Herlihy & 
Murphy, 1973), for data normalisation). Ratios of MIT values for post-agonist (last 30 
minutes prior to KPSS addition) relative to pre-agonist (last 30 minutes prior to cAMP 
agonist addition) treatment were calculated and converted to % MIT values.   
 
Tissue culture, isometric tension recording & data analysis for 24 hours prolonged 
treatment with cAMP agonists. 
Biopsies used for 24 hours pre-incubation to model ‘prolonged’ exposure to cAMP agonists 
were dissected under sterile conditions in cold DPBS and each attached to a glass weight of 
0.6-0.7 g mass to maintain them under tension once suspended in serum-free DMEM 
supplemented with penicillin-streptomycin; each longitudinal tissue strip measured 
approximately 8 x 2 x 1 mm between the two points at which they were tied to thread. The 
choice of 0.6-0.7 g mass was based on experimental data from a previous study (Cordeaux et 
al., 2010). Addition of cAMP agonists or vehicle controls to DMEM was done immediately 
before immersing tissues for incubation at 37
o
C in a humidified atmosphere of 95 % air/5 % 
CO2. Each tissue strip treated with a cAMP agonist was paired with a vehicle-treated strip 
from the same biopsy.  
After 24 hours, tissues were either (i) cut from their tied ends and into segments to weigh and 
snap freeze in liquid nitrogen for -80
o
C storage, or (ii) used for isometric tension recording 
experiments. For the former, untreated tissue pieces from matched biopsies were also snap 
frozen in liquid nitrogen to represent the state of the myometrium before 24 hours incubation, 
thus designated ‘t = 0’ (i.e. time zero).  We excluded db-cAMP from 24 hours incubation 
experiments because previous studies by others have suggested prolonged exposure to this 
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agonist can induce cAMP-independent cellular changes (Yusta et al., 1988; Seternes et al., 
1999). 
For isometric tension recordings, tissues, pre-incubated with cAMP agonists or vehicle, were 
mounted (after detaching their glass weights) into organ bath chambers and tension (29.4 
mN) applied; PSS was refreshed every hour thereafter. At the third PSS change, Syntocinon® 
(1 nM; synthetic oxytocin), PF 04418948 (10 µM; PGE2 receptor subtype 2 (EP2) 
antagonist), Bay K8644 (1 nM; L-type calcium channel (LTCC) agonist) or their vehicle 
controls was also added. For Bay K8644, each successive dose (or its vehicle) was added 
once every 25 minutes following a change of PSS each time. Subsequent incubations with 
KPSS, PSS washes, weighing, storage and data analysis were done in the same way as 
described for 1 hour acute response experiments. Absolute MIT values (in units of 
mN/s/mm
2
) were used for final representation of the data (instead of % MIT) for spontaneous 
(last 50 minutes prior to Syntocinon® treatment) and oxytocin-induced (last 30 minute prior 
to KPSS addition) contractions.  
 
Tissue homogenisation & PKA activity assay.  
One frozen segment of each tissue strip was homogenised in ice-cold extraction buffer (25 
mM Tris-HCl (pH 7.4), 0.5 mM EDTA and 0.5 mM EGTA), freshly supplemented with 
protease and phosphatase inhibitor cocktails as well as 10 mM β-mercaptoethanol,  using a 
bead-based homogeniser (TissueLyser II homogeniser (Qiagen; Manchester, UK) or 
Precellys 24 homogeniser (Stretton Scientific; Derbyshire, UK)); samples with identical 
experimental treatment protocols were extracted using the same homogeniser. Homogenates 
were centrifuged at 15700 g at 4
o
C for 5 minutes to isolate supernatants for assay, which 
were analysed for their relative protein concentrations using a Nanodrop ND-1000 
spectrophotometer (LabTech; East Sussex, UK). 
Manufacturer’s protocol for the PepTag® Non-Radioactive cAMP-Dependent Protein Kinase 
Assay kit (Promega; Southampton, UK) was used with the following modifications for 
measuring basal PKA activity in tissue extracts: (i) cAMP stock supplied with the kit was not 
added, and (ii) 0.04 ng PKA substrate was used for each sample and control reaction. Total 
protein of homogenate supernatants (18 µg) was used for each sample and the reaction 
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duration was 45 minutes. Agarose gel electrophoresis was used to separate florescent non-
phosphorylated and phosphorylated substrates, and gel images were captured using the Gel 
Logic 2200 Pro system (Carestream; Hertfordshire, UK) or G:BOX Chemical XL system 
(Syngene; Cambridge, UK); fluorescent gel bands were analysed by densitometry using 
ImageJ v1.46 software to obtain histogram-based total area pixel intensity values (National 
Institutes of Health; Maryland, USA), from which % phosphorylation of total assay substrate 
for each reaction was calculated.  
   
Western blotting. 
Protein samples from the same preparations of tissue extracts used for PKA assays were 
diluted in lithium dodecyl sulphate (LDS) sample buffer with 50 mM dithiothreitol for SDS-
PAGE; precast Bis-Tris gels were used for all primary antibody targets except smooth muscle 
myosin heavy chain (SM-MHC), which was examined using precast Tris-glycine gels. The 
same amount of protein (5-15 µg) was loaded into gel wells for paired cAMP agonist and 
vehicle control samples, and for each primary antibody target. Western blotting was done 
using the XCell SureLock Mini-Cell & XCell II Blot Module system (Life Technologies) for 
Bis-Tris gels or the Trans-Blot Turbo Transfer system (Bio-Rad) for Tris-glycine gels; both 
western blotting systems used polyvinylidene fluoride (PVDF) membranes. Ponceau-S 
staining was used to visualise transfer efficiency and identify suitable areas for membrane 
cutting.  
Membranes were blocked using 5 % w/v fat-free milk powder or bovine serum albumin 
(BSA) fraction V, both in Tween-Tris-buffered saline (TTBS), for un-phosphorylated and 
phosphorylated primary antibody targets, respectively. Duration of incubations with primary 
antibody (1-2 hours at room temperature or 10-16 hours at 4
o
C) and enhanced 
chemiluminescence (ECL) reagent (1-10 minutes) was dependent on the primary antibody 
used. Secondary antibody incubation lasted for 1-2 hours at room temperature. The G:BOX 
Chemical XL system was used to capture images of chemiluminescent bands on PVDF 
membranes after incubation with ECL reagent. Densitometry analysis was done using ImageJ 
v1.46 software to obtain histogram-based total area pixel intensity values, and these values 
for proteins of interest were normalised to those for either glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) or β-tubulin from the same gel lane for each sample.  
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Tissue pulverisation & cAMP enzyme immunoassay. 
One frozen segment of each tissue strip was pulverised into powder in liquid nitrogen using a 
stainless steel mortar and pestle. Extracts for cAMP quantification were prepared for enzyme 
immunoassay (EIA) using the DetectX Direct cAMP colorimetric EIA kit (Arbor Assays; 
Michigan, USA) following the manufacturer’s protocol. A MRX II microplate reader and 
Revelation v4.2.2 software (Dynex Technologies; West Sussex, UK) were used for data 
acquisition.  
 
Quantitative RT-PCR (qPCR). 
A segment of each frozen tissue strip was homogenised using a TissueLyser II homogeniser 
(Qiagen), RNA was extracted using the TRIzol® Plus RNA Purification kit (Life 
Technologies) and cDNA conversion was done using the QuantiTect Reverse Transcription 
kit (Qiagen). Primers were designed using Primer-BLAST (National Institutes of Health; 
Maryland, USA) and the sequences used are summarised in Table 3. HotStarTaq Master 
Mix (Qiagen) and QIAquick PCR Purification kits (Qiagen) were used for making qPCR 
standards for each set of primers using cDNA template of mRNA from untreated term non-
labouring human myometrial tissue. Amplicon size and purity of qPCR standards were 
checked using DNA agarose gel electrophoresis. RNA and cDNA concentrations were 
quantified using a Nanodrop ND-1000 spectrophotometer. SYBR® Green PCR Master Mix 
(Life Technologies) and a Rota-Gene Q thermocycler (Qiagen) were used for qPCR. Cycling 
conditions used and method of data analysis with Rotor-Gene Q Software v2.0.3 (Qiagen) 
were as previously described (Lei et al., 2011). 
   
Statistical analysis.  
Statistical analysis was performed using Prism v5.02 software (GraphPad; La Jolla, USA). 
Western blot data with n ≤ 5 was log-transformed for parametric analysis. Treated and 
control groups were classed as unmatched for all contractility data to take into account tissue 
strip-to-strip variability of muscle fibre orientations (Crankshaw et al., 2014). Statistical tests 
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used to identify significant differences (p < 0.05; indicated by one ‘*’ at all figures 
irrespective of exact p values) were as follows: Mann-Whitney, Wilcoxon or Kruskal-Wallis 
test (with Dunn’s post-hoc test for the latter) for isometric tension measurements; Wilcoxon 
or paired Student’s t-test for cAMP EIA and PKA activity; paired Student’s t-test for qPCR 
and western blot. Mean ± SEM values of fold differences calculated from cAMP agonist 
treatment relative to vehicle control are stated in the main text.   
 
RESULTS 
PKA-specific activation was not sufficient to mediate acute cAMP-driven relaxation. 
Spontaneous contractions were reduced by cAMP analogues 8-bromo-cAMP (Figure 1A-Ca) 
and db-cAMP (Figure 1A-Cb) in a concentration-dependent manner. In contrast to this, the 
PKA-specific agonist, 6-Bnz-cAMP, did not reduce spontaneous myometrial contractions 
(Figure 1A-Cc) despite significantly stimulating PKA activity (6.8 ± 2.0 mean fold versus 
vehicle for 0.2 mM, p = 0.0313; Figure 1Bc). Rolipram (Figure 1A-Cd), a PDE4-specific 
inhibitor, and forskolin (Figure 1A-Ce), an adenylyl cyclase activator, inhibited spontaneous 
contractions, but, intriguingly, both were associated with relatively low increases in PKA 
activity (Figure 1Dd-e). To emphasise the weak relationship between relaxation and PKA 
activation, 0.1 mM 8-bromo-cAMP had no effect on spontaneous contractions (p = 0.2188; 
Figure 1A-Da) but did increase PKA activity to a similar extent as 1 µM forskolin (2.0 ± 0.8 
and 2.0 ± 0.3 mean fold versus vehicle, respectively, and both p = 0.0313; Figure 1A-De).  
Concentrations of cAMP in tissues used for in vitro tension measurements (Figure 1) were 
higher than vehicle control for 1 µM rolipram (2.5 ± 0.4 mean fold versus vehicle, p = 
0.0132; Figure 2Aa), which was associated with a relatively small though nevertheless 
statistically significant increase in PKA activity (6.2 ± 3.8 mean fold versus vehicle, p = 
0.0313; Figure 1Dd). Forskolin increased cAMP content, but not to a significant extent (p = 
0.1070 (1 µM) and 0.2235 (10 µM); Figure 2Ab) even though PKA activity was increased, 
especially at 10 µM (5.4 ± 0.5 mean fold versus vehicle, p = 0.0313; Figure 1De), more 
robustly than rolipram. HSP20 Ser16-phosphorylation was increased by all cAMP agonists 
tested at their optimal pro-relaxation concentrations (Figure 2B); 6-Bnz-cAMP also increased 
HSP20 Ser16-phosphorylation despite failing to induce relaxation (Figure 1A-Cc). Double 
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bands were detected for both Ser16-phosphorylated and total HSP20 proteins, as reported 
previously (Karolczak-Bayatti et al., 2011; Sin et al., 2011); both were quantified and 
showed a similar pattern of change (Figure 2Bc, 2Bf). Levels of total HSP20 were unchanged 
in all cases except for a some reduction to its high molecular weight band form after 1 hour 
exposure to 1 mM db-cAMP (1.05 ± 0.2 mean fold versus vehicle, p = 0.0362; Figure 2Bd). 
For all subsequent western blots analysis, each phospho- and total HSP20 graph consists of 
values that equate to the sum of low and high molecular weight HSP20 bands detected 
together.  
  
Prolonged treatment with cAMP agonists alone was able to maintain enhanced PKA 
activity. 
Concentrations of cAMP agonists used for 24 hours treatment of tissues were those that gave 
≥ 80 % acute reduction of MIT in our 1 hour experiments (Figure 1); with the exception of 6-
Bnz-cAMP, for which 0.2 mM was used because it significantly activated PKA after acute 
treatment (Figure 1Dc). Myometrial tissues kept under tension during 24 hours treatment 
with 6-Bnz-cAMP or forskolin demonstrated higher PKA activity than vehicle controls (6.8 ± 
1.8 and 3.8 ± 0.7 mean fold, respectively, and both p = 0.0313; Figure 3A) as well as, to 
statistically borderline extent, 8-bromo-cAMP (4.5 ± 1.5 mean fold versus vehicle, p = 
0.0625; Figure 3Aa). Similar to our acute response data (Figure 1Dd), rolipram had no effect 
on PKA activity after 24 hours exposure (p = 0.1563; Figure 3Ab). HSP20 Ser16-
phosphorylation (Figure 3Ba-b) was increased by forskolin, (4.0 ± 0.7 mean fold versus 
vehicle, p = 0.0015), rolipram (2.7 ± 0.7 mean fold versus vehicle, p = 0.0334) and, to 
borderline significance, 8-bromo-cAMP (2.1 ± 0.5 mean fold versus vehicle, p = 0.0606). In 
contrast to 1 hour treatment of spontaneously contracting tissues (Figure 2), 6-Bnz-cAMP 
had no effect on HSP20 Ser16-phosphorylation levels after 24 hours of exposure (Figure 
3Ba). Total HSP20 protein levels were unchanged by cAMP agonists relative to their vehicle 
controls, but both H2O and DMSO vehicle treatment for 24 hours were associated with 
greater content of total HSP20 protein in tissues when compared to time zero controls (1.6 ± 
0.2, p = 0.0124, and 1.7 ± 0.1, p = 0.0008, mean fold versus time zero, respectively; Figure 
3Bc-d).  
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Spontaneous contractility was maintained by prolonged treatment with 8-bromo-cAMP.  
After assessing the ability of cAMP agonists to enhance PKA activity and/or HSP20 Ser16-
phosphorylation following 24 hours exposure alone (Figure 3), a second set of tissues was 
subjected to the same treatments, but then used for isometric tension measurements to 
determine the impact of prolonged incubation with cAMP agonists on myometrial 
contractility in vitro; overall spontaneous contractile output appeared to be reduced in tissues 
cultured for 24 hours compared to those used in our 1 hour experiments (prior to acute cAMP 
agonist or vehicle treatment; Figure 1A). Pre-incubation with 6-Bnz-cAMP had no effect on 
spontaneous contractility when compared to its vehicle control. However, in tissues treated 
with 1 mM 8-bromo-cAMP (4.3 ± 1.2 mean fold versus vehicle, p = 0.0043), rolipram (4.4 ± 
0.8 (1 µM) and 3.9 ± 1.2 (10 µM) mean fold versus vehicle; p = 0.0152 and 0.0260, 
respectively) and 10 µM forskolin (5.8 ± 1.5 mean fold versus vehicle, p = 0.0260), we 
observed greater spontaneous contractility (Figure 4Aa). In the case of 8-bromo-cAMP, this 
occurred despite elevated PKA activity as demonstrated in tissues from a third set of 
experiments (1.9 ± 0.3 mean fold versus vehicle, p = 0.0313; Figure 5A); Total calponin 
protein levels were increased in the same tissues (2.1 ± 0.3 mean fold versus vehicle, p = 
0.0210; Figure 5B). HSP20 Ser16-phosphorylation levels were reduced in these tissues but 
not to a statistically significant extent (0.8 ± 0.4 mean fold versus vehicle, p = 0.2387; Figure 
5C), while total HSP20 protein abundance was, on average, unchanged (Figure 5D). Cofilin 
Ser3-phosphorylation levels appeared, on average, unchanged (Figure 5E), while there was 
subtle, though not statistically significant, reduction of total cofilin protein abundance after 
prolonged exposure to 8-bromo-cAMP (0.9 ± 0.1 mean fold versus vehicle, p = 0.3509; 
Figure 5F).  
Oxytocin (1 nM Syntocinon®) stimulation was able to induce robust rhythmic contractions in 
both vehicle and cAMP agonist treated tissues, to similar extents, after 24 hours despite low 
spontaneous contractile output from the former (Figure 4Ab). The oxytocin-induced MIT 
values were not significantly greater in 8-bromo-cAMP pre-incubated tissues compared to 
vehicle control (Figure 4Ab-c). Interestingly, PKA activity measured after oxytocin 
stimulation (Figure 4B) was higher for tissues pre-incubated for 24 hours with 8-bromo-
cAMP (2.0 ± 0.3 mean fold versus vehicle, p = 0.0180) and 6-Bnz-cAMP (1.5 ± 0.1 mean 
fold versus vehicle, p = 0.0229).  
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We found no significant changes in protein levels for connexin-43 (Cx43), oxytocin receptor 
(OTR) and sarco/endo-plasmic reticulum calcium ATPase 2 (SERCA2) (data not shown). We 
also found no difference in SM-MHC or calponin (data not shown) levels after oxytocin 
stimulation. Levels of cyclic AMP-related proteins, PDE4B, PKA RIIα and GαS were also 
not different when compared to their vehicle controls (data not shown). A lack of difference 
in abundance of the same contraction-associated and cAMP signalling proteins was also 
noted for tissues measured only for their spontaneous contractile output after 24 hours pre-
incubation with 8-bromo-cAMP compared to vehicle control (data not shown). Interestingly, 
8-bromo-cAMP and rolipram pre-incubated tissues contained HSP20 Ser16-phosphorylation 
levels that were subtly lower than vehicle controls after oxytocin treatment (Figure 6Aa), 
which followed the same trend as observed for 8-bromo-cAMP pre-incubated strips measured 
only for their spontaneous contractions (Figure 5C). In addition to this, total HSP20 protein 
levels were found to be significantly reduced following oxytocin stimulation of tissues pre-
incubated with 8-bromo-cAMP (0.7 ± 0.04 mean fold versus vehicle, p = 0.0100; Figure 
6Ab). Total cofilin protein abundance was also slightly though significantly reduced (0.6 ± 
0.1 mean fold versus vehicle, p = 0.0189; Figure 6B).   
 
The effect of cAMP agonists on the prostaglandin system. 
Cyclooxygenase-2 (COX-2) protein levels were not affected by 24 hours incubation with 
cAMP agonists (Figure 7A). The mRNA expression levels for prostaglandin receptors and 
synthases, namely PGE2 receptor subtype 3 (PTGER3), PGE synthase types 1-3 (PTGES, 
PTGES2, PTGES3), PGF2α receptor variant 1 (PTGFR v1) and PGF synthase (PGFS), were 
also unaffected by pre-treatment with 8-bromo-cAMP compared to vehicle control (data not 
shown); PGE2 receptor subtypes 1 (PTGER1) and 4 (PTGER4), along with PGF2α receptor 
variant 2 (PTGFR v2), mRNAs were undetectable. Whereas PGE2 receptor subtype 2 
(PTGER2) mRNA levels were significantly greater in 8-bromo-cAMP pre-incubated strips 
(1.7 ± 0.1 mean fold versus vehicle, p = 0.0030), and assessment of tissues from equivalent 
experiments with the other cAMP agonists (Figure 4) showed the same, though to a slightly 
lesser extent, for 10 µM rolipram (1.6 ± 0.2 mean fold versus vehicle, p = 0.0055; Figure 7B). 
However, EP2 receptor antagonist, PF 04418948, treatment on a separate set of 8-bromo-
cAMP pre-incubated tissues during isometric tension measurements, in the absence of 
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oxytocin stimulation, showed the pro-relaxation effect of EP2 receptors was in fact 
functionally maintained to the same extent as vehicle pre-incubated tissues (Figure 7C).  
 
Myometrial contractions in the presence of a LTCC agonist were unaffected after 24 
hours treatment with 8-bromo-cAMP. 
LTCCs provide the main route of extracellular calcium entry (Tribe, 2001), are regulated by 
PKA (Chik et al., 1996; Zhong et al., 1999) and their activity is increased in the myometrium 
of labouring women (Longo et al., 2003). We used a non-cumulative dosing protocol with the 
LTCC agonist, Bay K8644, to identify any differences in the amount of contractile force 
generated from incrementally increasing the population of LTCCs in their open state after 
prolonged 8-bromo-cAMP incubation. Although tissues treated with 8-bromo-cAMP for 24 
hours tended to produce greater increases in contractile output after successive doses of Bay 
K8644 per unit of time, the MIT values for each dose were not significantly different to those 
of vehicle control (Figure 8).   
 
DISCUSSION 
In the current study, we sought to understand the role of PKA in acute cAMP-induced 
myometrial relaxation and to study the impact of prolonged maintenance of elevated cAMP 
levels on myometrial contractility. The latter aimed to assess the use of agents able to 
enhance cAMP levels without cell surface receptor activation for the prevention of preterm 
labour. We found that it was possible to significantly increase PKA activity without affecting 
spontaneous or induced myometrial contractility. This was unexpected given that it has long 
been held that cAMP acts via PKA to promote myometrial relaxation (Anwer et al., 1990; 
MacDougall et al., 2003; Tyson et al., 2008). Conversely, the prolonged maintenance of 
cAMP levels and PKA activity did not reduce spontaneous or oxytocin-induced myometrial 
contractions but, most notably in the case of 8-bromo-cAMP, actually resulted in greater 
spontaneous contractile output.   
 
The contribution of PKA to acute cAMP-driven myometrial relaxation.  
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The pro-relaxation concentrations we determined for 8-bromo-cAMP, rolipram and forskolin, 
by applying these cAMP agonists to spontaneously contracting tissues as single doses for 1 
hour incubation, matched well with previous studies that used the same cAMP agonists to 
observe cumulative dosing effects (Mehats et al., 2000; Slater et al., 2006; Tyson et al., 
2008). The ability of cAMP to acutely inhibit myometrial contractions is often attributed to 
PKA activation (Tyson et al., 2008; Karolczak-Bayatti et al., 2011). Indeed our experiments 
showed that tissues treated with pro-relaxation concentrations of 8-bromo-cAMP and db-
cAMP contained significantly higher levels of PKA activity than those treated with vehicle 
control.  
However, the findings of our present study also demonstrated acute PKA activation alone 
does not mediate relaxation in human myometrial tissue despite being able to promote HSP20 
Ser16-phosphorylation, as shown by (i) lack of pro-relaxation effects from a PKA-specific 
agonist, 6-Bnz-cAMP, and (ii) lack of correlation between PKA activity and degree of 
relaxation achieved with different cAMP agonists. The latter was clearly demonstrated by 
rolipram’s ability to induce myometrial relaxation without significantly increasing PKA 
activity, as well as by forskolin’s ability to induce profound relaxation with modest PKA 
activation necessary. These data suggest other cAMP signalling components may be 
necessary for promoting myometrial relaxation, such as PDE4. Indeed, in cardiomyocytes, 
PDE4 binds to HSP20 to prevent its phosphorylation by PKA (Sin et al., 2011); HSP20 
activation, which leads to muscle relaxation by promoting actin depolymerisation via cofilin 
(Karolczak-Bayatti et al., 2011), occurs when cAMP levels are increased in close physical 
proximity to PDE4, by stimulating its dissociation from HSP20. If a similar sequence of 
events occurs in myometrial cells, it suggests that cAMP analogues activate PKA, but do not 
induce relaxation at low concentrations due to their indiscriminate intracellular distribution. 
Indeed, both 8-bromo-cAMP and db-cAMP are poor PDE substrates, compared to 
endogenous cAMP, but are able to saturate PDE4 active sites when present in high 
concentrations (Schultz et al., 1994; Xu et al., 2004), perhaps explaining why their ability to 
increase PKA activity preceded their pro-relaxation effects. However, 6-Bnz-cAMP also has 
a low affinity for PDE4 (Poppe et al., 2008) while still able to promote HSP20 Ser16-
phosphorylation without inducing relaxation, suggesting a yet to be elucidated distinction in 
PKA-independent aspects of cAMP-driven muscle relaxation between the heart and 
myometrium.  
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Our detection of low PKA activity despite measurable increases in cAMP levels following 
rolipram treatment, as well as high PKA activity despite less detectable levels of cAMP 
elevation following forskolin treatment, could be attributed to the activation status of 
adenylate cyclases (ACs) playing more of an important role towards the amount of PKA 
activity achieved than the amount of cAMP they synthesise in total. Microdomain cAMP 
signalling is also an important potential contributor, especially when considering that the 
present study measured PKA activity and intracellular cAMP concentrations using whole 
tissue extracts, and thus any intracellular localised elevations of both would have been diluted 
once tissues were homogenised. PDE4 inhibition by rolipram would reduce the hydrolysis of 
cAMP in myometrial cells in a resting state, as AC activity is unlikely to be enhanced by 
rolipram treatment. On the other hand, forskolin treatment mimics Gαs-coupled GPCR 
activation by directly enhancing AC activity. Thus, we could speculate that the active 
conformation of ACs sensitise PKA activity, via mechanisms such as protein-protein 
interactions via lipid rafts (Crossthwaite et al., 2005) and A-kinase anchoring proteins 
(AKAPs), to minimise the amount of cAMP necessary for its enhancement. In the latter case, 
it is also well-established that ACs and PKA are often held in close proximity to each other 
via AKAP79, a protein that is known to be expressed in human myometrial tissue (Ku et al., 
2005), to form efficient signalling complexes (Cooper & Tabbasum, 2014).    
If we also speculate that cAMP-hydrolysing PDEs control cAMP levels in specific 
intracellular microdomains, such as around the local vicinity of ACs and PKA at the plasma 
membrane of intact cells, and prevent its diffusion via region-restricted hydrolysis, which 
would explain why the total amount of cAMP would appear low when measured from whole 
tissue extract following forskolin treatment. Whereas PDE4 inhibition by rolipram would 
cause loss of localised cAMP elevation (Houslay, 2010), which could increase total cellular 
levels of cAMP sufficiently to make it detectable via enzyme immunoassays, after acute 
treatment, but at the same time not appear to significantly increase PKA activity levels due to 
the absence of necessary interactions between ACs and PKA. The apparent lower potency of 
8-bromo-cAMP, db-cAMP and 6-Bnz-cAMP towards mediating myometrial relaxation, 
relative to PKA activity enhancement, may also be attributed to their lack of effect on AC-
related interactions, in addition to their low binding affinity for PDE4. The importance of 
microdomain cAMP signalling is becoming increasingly well-defined in both cardiovascular 
(Zaccolo & Pozzan, 2002; Sprenger et al., 2015) and airway smooth muscle (Bogard et al., 
  
 
This article is protected by copyright. All rights reserved. 
18 
 
2011; Patel et al., 2015), but is relatively less explored in human myometrial smooth muscle 
(Dodge et al., 1999; Mehats et al., 2000; MacDougall et al., 2003).  
Previously published enzyme kinetics data gathered using purified proteins (Poppe et al., 
2008) have shown 8-bromo-cAMP and 6-Bnz-cAMP are capable of activating protein kinase 
G (PKG), but their half-maximal activation constants are >60-fold higher than for PKA. 
Nevertheless, we cannot discount the possibility that high concentrations of these agonists, 
such as those required for near-complete cessation of spontaneous contractions at acute 
response experiments, could activate the cGMP pathway. Indeed, it is known that HSP20 can 
be phosphorylated at its Ser16 residue by PKG (Beall et al., 1997). Protein structure analysis 
has previously shown forskolin is unlikely to be able to activate cGMP synthesis, at least via 
soluble guanylate cyclase activation (Allerston et al., 2013), and biochemical studies have 
shown forskolin itself is unable to mediate cell-based cGMP elevation (Watson et al., 1990). 
Similar studies have also been done to show rolipram is specific to cAMP-hydrolysing PDEs 
(Delpy et al., 1996; Herman et al., 2000). Thus forskolin and rolipram treatment are likely to 
be associated with greater specificity for the activation of signalling via cAMP rather than 
cGMP when compared to the cAMP structural analogues, which may partly explain why they 
differ in their efficiencies for promoting myometrial relaxation during short-term exposure. 
 
The impact of prolonged cAMP agonist exposure on myometrial spontaneous 
contractility and PKA activity. 
Spontaneous contractility of tissues after 24 hours incubation was notably greater after 
incubation with 8-bromo-cAMP and, to a lesser though nevertheless significant extent, with 
rolipram and forskolin. Tissues pre-incubated with 8-bromo-cAMP also demonstrated 
increased calponin, as well as hinted towards reduced levels of both HSP20 Ser16-
phosphorylation and total cofilin protein. Calponin has been shown to increase myometrial 
contractility in mice (Li et al., 2012), cofilin promotes actin depolymerisation when not 
phosphorylated at its Ser3 residue and HSP20 Ser16-phosphorylation promotes activation of 
cofilin (Karolczak-Bayatti et al., 2011; Hocking et al., 2013). Consequently, these protein-
level changes observed after prolonged exposure to 8-bromo-cAMP may have contributed to 
the relatively greater spontaneous myometrial contractility we observed. The reduction in 
HSP20 Ser16-phosphorylation detected after contractility measurements with 8-bromo-
  
 
This article is protected by copyright. All rights reserved. 
19 
 
cAMP pre-incubated tissues occurred despite elevated PKA activity and thus may be 
attributed to increased phosphatase activity.  Indeed, phosphatases have been suggested to 
play an important role in the propagation of rhythmic contractions via tightly controlling 
contractile apparatus-regulating protein phosphorylation (Butler et al., 2013), although this 
aspect of myometrial function has not been well-explored beyond examining myosin light 
chain phosphatase (MYLP, a protein phosphatase 1 holoenzyme; (Hudson et al., 2012). 
Calcineurin, also known as calcium-activated protein phosphatase 2B, dephosphorylates 
cofilin to control tracheal smooth muscle contractility (Zhao et al., 2008) and may play a 
similar role in the myometrium (Ayres et al., 2003). Another possible explanation for the 
decline in HSP20 Ser16-phosphorylation may be attributed to 8-bromo-cAMP being able to 
activate PKG when used at high concentrations (as discussed above) and thus negative 
feedback on HSP20 Ser16-phosphorylation may have originated from the prolonged 
activation of PKG instead of altered PKA activity; the same possibility could also apply to 
the loss of HSP20 Ser16-phosphorylation following prolonged exposure to 6-Bnz-cAMP. 
The increase in total HSP20 protein levels following 24 hours in tissue culture relative to 
‘time zero’ control samples, irrespective of cAMP agonists or vehicle treatment conditions, 
would appear to be consistent with the decline in spontaneous contractile output of all except 
8-bromo-cAMP pre-incubated tissues, and most likely attributed to the in vitro culture 
conditions not being an exact replication of the in utero environment.       
Despite a profound enhancement of spontaneous contractile output following prolonged 
exposure to 8-bromo-cAMP, we found that alterations to levels of several contraction-
associated and cAMP signalling proteins often recognised as markers of labour in the 
myometrium were not necessary for this observation made in the present study. This included 
COX-2 protein, which was in conflict with our previous findings from cultured myometrial 
cells that showed prolonged treatment with cAMP agonists can enhance its expression levels 
(Chen et al., 2012). This discrepancy could be attributed to a difference in complexity of the 
extracellular environment that exists between passaged myometrial cells grown in monolayer 
formation and tissue-based myometrial cells bound to a three-dimensional extracellular 
matrix alongside other cell types, which may cause differences in response to cAMP agonists 
due to, for example, greater buffering effects experienced by the latter. We detected no 
differences in the expression of several mRNA transcripts for receptors and synthetic 
enzymes of the prostaglandin pathway (Astle et al., 2005; Astle et al., 2007; Hay et al., 2010) 
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in 8-bromo-cAMP pre-incubated tissues (after oxytocin exposure), with the exception of 
PTGER2 mRNA that encodes EP2 receptors. Interestingly, EP2 receptors can change their G 
protein coupling from pro-relaxation Gαs to pro-contractile Gαq upon labour onset in 
myometrial cells (Kandola et al., 2014). We hypothesised prolonged exposure to 8-bromo-
cAMP promoted spontaneous contractions by up-regulating Gαq-coupled EP2 receptor 
activity, and thus expected a decline in spontaneous contractions from 8-bromo-cAMP pre-
incubated tissues when acutely treated with EP2 receptor-specific antagonist, PF 04418948, 
but we found this to not be the case.        
The 8-bromo-cAMP-induced increase in intracellular cAMP activity is relatively PDE-
resistant and may actually drive the pro-contractile changes we observed as part of a negative 
feedback response. Indeed, such a response has been reported for primary myometrial cells, 
which increase their PDE4 enzyme activity (Mehats et al., 1999) and decrease their GαS gene 
promoter activity (Phillips et al., 2002) after exposure to forskolin for 5 hours or more. In our 
experiments, forskolin and rolipram enhanced spontaneous contractions to a relatively lesser, 
but nevertheless significant, extent than 8-bromo-cAMP after 24 hours exposure, which may 
be attributed to the more hydrolysable nature of endogenous cAMP compared to the 
structural analogue form of 8-bromo-cAMP. This apparent time-dependent role reversal in 
cAMP control of myometrial activity, from pro-relaxation to pro-contractile, may contribute 
to the β2-agonist tolerance effect seen from their use as tocolytics by modulating signalling 
processes beyond the cell surface receptors. Thus it may not be possible to by-pass 
desensitization of cAMP-mediated uterine relaxation associated with β2-adrenoreceptor 
activation via use of receptor-independent cAMP agonists alone. Glucocorticoids prevent β2-
adrenoceptor agonists-induced desensitization (Mak et al., 1995) and it is possible that the 
combination of progesterone and a cAMP agonist may have a similar effect in the 
myometrium. Indeed, we have previously published work to suggest cAMP agonists could be 
combined with progesterone to improve efficacy of the latter in reducing myometrial 
inflammation (Chen et al., 2014) and are currently assessing the possibility that this 
combination could also better reduce contractile output of myometrial tissue than either agent 
alone.    
Since the PKA-specific activator we assessed had no effect on spontaneous contractility, it is 
possible that the effects of 8-bromo-cAMP are mediated through a cAMP-dependent 
interaction with proteins other than PKA. The lack of change in both EP2 receptor and LTCC 
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function after 8-bromo-cAMP pre-incubation suggests the activity of these proteins did not 
contribute to the greater spontaneous contractile output that resulted from this treatment. 
Another potential candidate is EPAC, which binds directly to cAMP with an affinity that 
closely matches that of PKA (Dao et al., 2006), but it is able to act independently of PKA 
activity in vascular and airway smooth muscle cells (Kassel et al., 2008; Purves et al., 2009; 
Eid, 2012). Its function in myometrial tissue is unknown, but EPAC and PKA have been 
shown to work together to inhibit smooth muscle proliferation and enhance contractility in 
airway smooth muscle cells (Hewer et al., 2011; Roscioni et al., 2011a).  
 
The impact of prolonged cAMP agonist exposure on myometrial contractility and PKA 
activity after oxytocin stimulation. 
All cAMP agonists failed to prevent oxytocin-induced contractions after prolonged exposure, 
despite detectable enhancement of PKA activity and/or HSP20 Ser16-phosphorylation (to a 
similar extent as observed with acute relaxation from 1 hour of treatment) after 24 hours of 
pre-incubation alone. It has been previously reported that 48 hours of cAMP elevation can 
enhance both SM-MHC and calponin expression in myometrial tissue, as well as increase 
oxytocin-induced contractile output (Fetalvero et al., 2008). Connexin-43 (Cx43), oxytocin 
receptor (OTR) and sarco/endo-plasmic reticulum calcium ATPase 2 (SERCA2) have all 
been previously identified as contraction-associated proteins in the myometrium (Kimura et 
al., 1996; Sparey et al., 1999; Tribe et al., 2000). However, our oxytocin-treated tissues 
showed no significant change in the levels of these proteins associated with the contractile 
apparatus and cAMP signalling. Instead, where we detected subtle decreases in total cofilin 
and HSP20 Ser16-phosphorylation in tissues that demonstrated enhanced spontaneous 
contractile output following pre-incubation with 8-bromo-cAMP, both also showed a decline 
in abundance following oxytocin stimulation. Together, our data from these experiments 
suggest prolonged activation of cAMP signalling does not result in lasting changes to the 
abundance of key proteins previously suggested to characterise myometrial labour-induced 
changes, both in the event of oxytocin-mediated augmentation of contractions and enhanced 
spontaneous contractions caused by prolonged exposure to 8-bromo-cAMP.  
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Summary. 
In conclusion, the relationship between PKA activity and contractile output within the human 
myometrium is not a direct one. Other components of the cAMP signalling pathway are 
likely to make greater direct contributions towards mediating its well-recognised acute pro-
relaxation effects, such as ACs and PDEs, with the control of intracellular microdomain 
signalling also playing a key role. Our novel observation of 8-bromo-cAMP’s ability to 
promote spontaneous contractions, after prolonged exposure, demonstrates the potential 
importance of duration and spatial distribution of cAMP signalling in the regulation of 
myometrial contractility (Figure 9-10); it is unlikely to be related exclusively to PKA 
activation and potentially involves other cAMP-sensitive proteins or even alternative 
pathways, especially those of influence to the dynamics of actin filament function. Our 
findings suggest that prophylactic use of receptor-independent cAMP agonists alone, with 
intent to ubiquitously enhance myometrial cAMP accumulation and PKA activity, is unlikely 
to prevent the onset of preterm labour in high-risk women. However, cAMP modulation 
could remain a potential therapeutic target, if the need to control the intensity of cAMP 
augmentation necessary to maintain its pro-relaxation effects and a strategy to  avoid negative 
feedback is considered. This may require combining its beneficial actions with those of 
tocolytic agents that act on alternative pathways to provide the balance required to achieve 
myometrial quiescence. 
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FIGURE LEGENDS 
Figure 1. Disparity in effectiveness of cAMP agonists (1 hour exposure) to reduce 
spontaneous contractility of pregnant human myometrial tissue compared to PKA 
activation. Absolute mean integral tension (MIT) values for 30-minute period immediately 
prior to (A) addition of treatment and (B) end of 1 hour incubation with cAMP agonist or 
vehicle control, which were used to calculate (C) % MIT of spontaneously contracting human 
myometrial tissues in vitro for different concentrations of (a) 8-bromo-cAMP, (b) db-cAMP, 
(c) 6-Bnz-cAMP, (d) rolipram and (e) forskolin; representative traces of tension changes 
during contractions before and, as indicated by horizontal lines, during cAMP agonist or 
vehicle control treatment are also shown. (D) Protein kinase A (PKA) activity content of 
homogenate extracts from the same tissues, calculated as % phosphorylation of total assay 
substrate, alongside representative gel images of phosphorylated (‘+’) and non-
phosphorylated (‘-‘) PKA activity assay substrate after agarose gel electrophoresis for pair-
matched vehicle control (‘C’) and cAMP agonist (‘T’) treated samples. All data presented as 
mean ± SEM (n = 6); statistically significant differences between cAMP agonist and vehicle 
control treatment denoted by * (p < 0.05) and ‘P=0.06’ for borderline significance (p = 
0.0649 for 0.1 µM rolipram versus vehicle control in (Bd); p = 0.0649 for 0.2 mM 8-bromo-
cAMP versus vehicle control in (Ca)).  
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Figure 2. Intracellular cAMP concentrations and HSP20 Ser16-phosphorylation levels 
did not correlate with intensity of relaxation and PKA activity achieved after incubating 
spontaneously contracting pregnant human myometrial tissue with cAMP agonists for 1 
hour. Tissue cAMP content quantified by enzyme immunoassay (EIA) for spontaneously 
contracting tissues treated for 1 hour with either (Aa) rolipram or (Ab) forskolin (same 
tissues as represented in Figure 1) presented as mean ± SEM (n = 6). Phosphorylated and 
total heat shock protein 20 (HSP20) levels for (Ba, Bd) ~19 kDa (‘high’) and (Bb, Be) ~17 
kDa (‘low’) molecular weight protein bands, detected by western blotting with the same 
protein extracts used for protein kinase A (PKA) activity assays shown in Figure 1, presented 
as mean ± SEM (n = 4-5). Statistically significant differences are denoted by * (p < 0.05) for 
both (A) and (B). Representative western blot images for (Bc) Ser16-phosphorylated 
(‘Phospho-HSP20’) and (Bf) total HSP20 protein are shown below their corresponding 
graphs, alongside their matched glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
loading controls; positions of ‘high’ (thick arrow) and ‘low’ (thin arrow) HSP20 bands 
indicated next to each immunoblot image of pair-matched vehicle control (‘C’) and cAMP 
agonist (‘T’) treated samples.  
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Figure 3. Treatment of pregnant human myometrial tissue maintained under tension 
for 24 hours with cAMP agonists enhanced PKA activity and HSP20 Ser16-
phosphorylation to differing extents. Protein kinase A (PKA) activity measured from 
protein extracts of tissues incubated with (Aa) H2O- (8-bromo-cAMP and 6-Bnz-cAMP) or 
(Ab) DMSO- soluble (rolipram and forskolin) cAMP agonists for 24 hours; untreated tissue 
samples snap frozen in liquid nitrogen at time of initiating treatment at tissue strips, dissected 
from matched biopsies, (‘time zero’, t = 0) were also assessed. PKA activity data presented as 
mean ± SEM (n = 6). Representative gel images of phosphorylated (‘+’) and non-
phosphorylated (‘-’) PKA assay substrate shown below corresponding graphs, with labels for 
time zero (‘t0’), 8-bromo-cAMP (‘8Br’), 6-Bnz-cAMP (‘6BC’), H2O vehicle (‘H2O’), 
rolipram (‘RP’), forskolin (‘FSK’) and DMSO vehicle (‘DMSO’). Ser16-phosphorylated and 
total heat shock protein 20 (HSP20) levels for (Ba, Bc) H2O- and (Bb, Bd) DMSO- soluble 
cAMP agonists in the same protein extracts represented in (A), as determined via western 
blotting, for which data is presented as mean ± SEM of the sum of values for low and high 
bands detected together (n = 5). For both (A) and (B), statistically significant differences are 
denoted by * (p < 0.05) and ‘P=0.06’ for borderline significance (p = 0.0625 for 1 mM 8-
bromo-cAMP versus H2O in (Aa); p = 0.0606 for 1 mM 8-bromo-cAMP versus H2O in (Ba)). 
Representative western blot images for Ser16-phosphorylated (‘P-HSP20’) and total (‘T-
HSP20’) HSP20 protein levels are shown below their corresponding graphs, alongside their 
matched glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading controls, with the 
same labels representing each treatment as used for representative PKA assay gel images 
shown in (A); positions of ‘high’ (thick arrow) and ‘low’ (thin arrow) HSP20 bands are also 
indicated.  
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Figure 4. Treatment of pregnant human myometrial tissue for 24 hours with 8-bromo-
cAMP simultaneously enhanced spontaneous contractions and PKA activity. Ability of 
myometrial tissues to contract both (Aa) spontaneously and subsequently (Ab) in response to 
oxytocin (1 nM Syntocinon®) measured after 24 hours treatment with cAMP agonists or 
vehicle controls, presented as absolute mean integral tension (MIT). Spontaneous 
contractions measured from 50 minutes immediately before oxytocin addition. Oxytocin-
augmented contractions measured from last 30 minutes of 1 hour incubation with the 
hormone. (Ac) Representative traces of contractile output measured from tissues pre-
incubated for 24 hours with 8-bromo-cAMP or vehicle control, showing contractions before 
and during, as indicated by the horizontal line, 1 nM oxytocin stimulation. (B) Protein kinase 
A (PKA) activity contents in protein extracts of the same tissues represented in (A) calculated 
as % phosphorylation of total assay substrate; Statistically significant differences denoted by 
* (p < 0.05) for both (A) and (B). Data presented as mean ± SEM (n = 6) for all graphs. 
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Figure 5. Enhanced spontaneous contractions after 24 hours treatment of pregnant 
human myometrial tissue with 8-bromo-cAMP was associated with enhanced calponin 
protein abundance but minor changes for both HSP20 and cofilin phosphorylation 
levels. Total protein extracts of tissues treated for 1 hour with DMSO (i.e. PF 04418948 
vehicle control) during spontaneous contractions, as represented in Figure 7C, were measured 
for (A) total protein kinase A (PKA) activity content, as well as protein abundance of (B) 
calponin, (C) heat shock protein 20 (HSP20) Ser16-phosphorylation, (D) total HSP20, (E)  
cofilin Ser3-phosphorylation and (F) total cofilin. For phospho- and total HSP20 protein 
graphs, data is shown as the sum of values for low and high HSP20 bands detected together at 
western blots. All values presented as mean ± SEM for PKA activity (n = 6) and western 
blotting (n = 5) data; statistically significant differences denoted by * (p < 0.05). A typical 
agarose gel image of phosphorylated substrate from a PKA activity assay represented by (A) 
is shown above its associated graph. Representative western blot images for calponin, Ser16-
phosphorylated HSP20 (‘P-HSP20’), total HSP20 (‘T-HSP20’), Ser3-phosphorylated cofilin 
(‘P-cofilin’) and total cofilin (‘T-cofilin’) are shown above their associated graphs, alongside 
matched images for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or β-tubulin 
loading controls; positions of ‘high’ (thick arrow) and ‘low’ (thin arrow) HSP20 bands are 
also indicated. For all representative images of agarose gels and western blots, paired samples 
of tissues pre-incubated for 24 hours with H2O (‘C’) or 1 mM 8-bromo-cAMP (‘T’) prior to 
isometric tension measurements for spontaneous contractile output are shown.  
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Figure 6. Treatment of pregnant human myometrial tissues for 24 hours with 8-bromo-
cAMP and rolipram, with subsequent contractility measurements, reduced levels of 
HSP20 Ser16-phosphorylated and total cofilin proteins. (Aa) Ser16-phosphorylated and 
(Ab) total heat shock protein 20 (HSP20) protein levels were assessed by western blotting; 
protein extracts were prepared from tissues pre-incubated for 24 hours with cAMP agonists 
or their vehicle controls, and subsequently used for isometric tension measurements for both 
spontaneous and oxytocin-induced contractions (i.e. same samples represented in Figure 4). 
Each graph shows the sum of values for low and high HSP20 bands detected together. (Ac) 
Representative images of western blots for Ser16-phosphorylated (‘Phospho-HSP20’) and 
total HSP20 protein, alongside their sample-matched glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) loading controls; positions of ‘high’ (thick arrow) and ‘low’ (thin 
arrow) HSP20 bands for pair-matched vehicle control (‘C’) and cAMP agonist (‘T’) pre-
incubated samples are indicated next to each immunoblot image. (B) Total cofilin protein 
levels were also measured via western blotting for all 6 treatment conditions represented in 
Figure 4; corresponding data shown alongside representative western blot images for total 
cofilin and sample-matched GAPDH. Data presented as mean ± SEM for all graphs, where n 
= 3-4 for (Aa) and (Ab), n = 5 for (B); statistically significant differences between cAMP 
agonist and vehicle treatment denoted by * (p < 0.05) and, in the case of (Aa) and (Ab), p 
values also given where n = 4 but did not pass the p < 0.05 threshold. 
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Figure 7. PTGER2 mRNA levels are increased after 24 hours treatment with 8-bromo-
cAMP and rolipram, but did not correlate with a change to EP2 function in pregnant 
human myometrial tissue. Abundance of (A) cyclooxygenase-2 (COX-2) protein and (B) 
PGE2 receptor subtype 2 (PTGER2, known as EP2 receptor at the protein level) mRNA from 
homogenate extracts of the same tissues represented in Figure 4 as determined using western 
blotting and qPCR, respectively. Data presented as mean ± SEM; statistically significant 
differences for COX-2 protein (n = 5) and PTGER2 mRNA (n = 6) are denoted by * (p < 
0.05). For qPCR data at (B), the threshold cycle (‘CT’) range for PTGER2 is also stated. (C) 
A separate set of tissues pre-incubated with 8-bromo-cAMP or its vehicle (‘H2O’) for 24 
hours prior to isometric tension measurements, from which spontaneous mean integral 
tension (MIT) was calculated from 30 minutes immediately before addition of, and final 30 
minutes of incubation with, either EP2 receptor-specific antagonist, 10 µM PF 04418948 (‘10 
µM PF’) or its vehicle (‘DMSO’). Statistically significant differences were identified for the 
following comparisons: (Ca) MIT between 8-bromo-cAMP and H2O vehicle pre-incubated 
strips before addition of PF 04418948 or DMSO vehicle, denoted by ‘a’ (p < 0.05), and MIT 
before and after treatment with PF 04418948, denoted by ‘b’ (p < 0.05); (Cb) change in MIT 
(‘ΔMIT’) after PF 04418948 treatment, denoted by * (p < 0.05). All MIT data presented as 
mean ± SEM (n = 8).  (Cc) Representative traces of contractile output measured from tissues 
before and during, as indicated by the horizontal line, 10 µM PF 04418948 (“PF044”) 
treatment. 
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Figure 8. Dose-dependent spontaneous contractile responses to L-type calcium channel 
agonist Bay K8644 by pregnant human myometrial tissues were not significantly altered 
after 24 hours treatment with 8-bromo-cAMP. Spontaneous contractility of tissues pre-
incubated for 24 hours with either 8-bromo-cAMP or its H2O vehicle prior to and after non-
cumulative dosing with Bay K8644. (A) Mean integral tension (MIT) calculated from 15 
minutes prior to starting dosing with either Bay K8644 or its DMSO vehicle (indicated in 
brackets); statistically significant differences are denoted by * (p < 0.05).  (Ba) Difference in 
MIT (ΔMIT) between the last 15 minutes of exposure to each corresponding dose of Bay 
K8644 or DMSO vehicle and last 15 minutes of spontaneous MIT prior to first dose of Bay 
K8644 (10
-9
 M) or DMSO vehicle (i.e. MIT values presented in (A)). (Bb) ΔMIT corrected 
for per contraction measured during treatment with associated Bay K8644 dose (instead of 
per unit time), and (Bc) contraction frequency during time period analysed. Statistically 
significant differences for all figures in (B) were not found in all cases (p > 0.05). All data 
presented as mean ± SEM (n = 8) for all graphs. (Bd) Representative traces of contractile 
output measured from tissues before and during Bay K8644 treatment, with arrows indicating 
time points at which a dose of the LTCC agonist was added.   
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Figure 9. Directions of enhanced cAMP activity flow upon cAMP agonist treatment in 
pregnant human myometrial tissue. Schematic diagram of cAMP signalling targets and 
their activation status within myometrial cells of intact tissue during stimulation with cAMP 
agonists (labelled on the left of each associated scenario). Basal (i.e. endogenous cAMP at 
resting state) and enhanced (i.e. endogenous and analogue-based cAMP action during 
stimulated state) activities are indicated by the empty and filled shapes, respectively. 
Adenylate cyclase (‘AC’), protein kinase A (‘PKA’) and phosphodiesterase 4 (‘PDE4’) are 
all established targets of signalling activity upon cAMP agonist treatment. Heat shock protein 
20 (‘HSP20’) is a contractile apparatus-associated substrate (at its Ser16 residue) for both 
PKA and protein kinase G (‘PKG’), though the activity of the latter is expected to be the 
lowest of the two kinases during exposure to all cAMP agonists tested. ‘Exchange protein 
directly activated by cAMP’ (‘EPAC’) has been included as a representative of alternative 
cAMP-binding proteins yet to have their actions in the myometrium fully elucidated.   
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Figure 10. Proposed relationships between spatial distribution of enhanced cAMP 
signalling and its time-sensitive effects on spontaneous contractility in pregnant human 
myometrial tissue. Schematic diagram of cAMP signalling targets within a typical tissue-
based myometrial cell (with the nucleus (‘Nu’) and endoplasmic reticulum (‘ER’) shown) and 
proposed distribution of enhanced cAMP signalling activity during ‘acute’ (1 h) and 
‘prolonged’ (24 h) exposure to cAMP agonists (labelled on the left of each associated pair of 
scenarios). Their effects on spontaneous contractility are stated below each scenario, whereby 
the sizes of the arrows indicate relative intensity of change to contractile force. Basal (i.e. 
endogenous cAMP at resting state) and enhanced (i.e. endogenous and analogue-based cAMP 
action during stimulated state) activities are indicated by empty and filled shapes, 
respectively; shading within the cytosolic area indicate proposed intracellular locations of 
elevated cAMP-driven activity highly capable of acting on multiple targets. Proteins depicted 
are as follows: protein kinase A (‘PKA’), adenylate cyclase (‘AC’), heat shock protein 20 
(‘HSP20’), phosphodiesterase 4 (‘PDE4’), A-kinase anchoring protein (‘AKAP’), G protein-
coupled receptor (‘GPCR’) and G protein αs (Gαs; βɣ subunits have not been included to 
simplify the diagram). The positions of PKA (specifically regulatory subunits), HSP20 and 
AKAP are inferred from previous myometrium-based studies, while that of PDE4 is 
speculated.  
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Table 1: Patient Demographics for Myometrial Tissue Samples  
 1 h acute treatment 
(data presented: n = 49; qPCR 
templates for standards: n = 2)  
 
24 h pre-incubation  
(data presented: n = 36) 
Maternal 
age (years; 
median with 
range)  
 
34 (21-46) 36 (26-46) 
Gestational 
age (weeks; 
median with 
range) 
 
39 (37.7-41.6) 39 (38.0-41.1) 
Gravida 
(median 
with range) 
 
2 (1-7) 
 
2 (1-8) 
Parity 
(median 
with range) 
 
1 (0-3; live births)  
+ 0 (0-4; non-viable & abortus) 
 
1 (0-3; live births)  
+ 0 (0-6; non-viable & abortus)  
Booking 
BMI 
(median 
with range) 
 
23 (17-42) 23 (18-33) 
Ethnicity   34 White European 
 6 White other 
 2 Black African & Caribbean 
 2 Asian 
 4 Other  
 3 Not disclosed  
 
 18 White European 
 0 White other 
 5 Black African & Caribbean 
 5 Asian 
 4 Other  
 4 Not disclosed  
 
Reason for 
Caesarean 
 25 Previous Caesareans 
 15 Breech 
 8 Other maternal clinical indication 
(GDM and PET excluded from 
study) 
 2 Maternal request 
 1 Tocophobia  
 
 22 Previous Caesareans 
 4 Breech 
 7 Other maternal clinical indication 
(GDM and PET excluded from 
study) 
 3 Maternal request 
 0 Tocophobia  
 
Primary antibody target Supplier (catalog no.) Dilution 
Phospho (Ser16)- he t shock protein 20 (HSP20) Abcam ( b58522) 1:10,000 
Total heat shock protein 20 (HSP20) Abcam (ab184161) 1:80,000 
Connexin-43(Cx43) New England BioLabs (#3512) 1:1,000 
Oxytocin receptor (OTR) Santa Cruz (sc-8102) 1:1,000 
Cyclooxygenase-2 (COX-2) Santa Cruz (sc-1745) 1:1,000 
Calponin Abcam (ab46794) 1:20,000 
Sarco/endo-plasmic reticulum calcium ATPase 2 
(SERCA2) 
Abcam (ab2817) 1:1,000 
S ooth muscle myosin heavy chain (SM-MHC) Millipore (MAB3568) 1:10,000 
Phosphodiesterase 4B (PDE4B) Abcam (ab112014) 1:500 
Protein kinase A regulatory subunit 2α (PKA RIIα) Abcam (ab38949) 1:500 
G protein αs (Gαs) Abcam (ab83735) 1:4,000 
Phospho (Ser3)-cofilin  New England BioLabs (#3311) 1:500 
Total cofilin  New England BioLabs (#3312) 1:500 
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) 
Millipore (MAB374) 1:40,000 
β-tubulin  Abcam (ab21057) 1:1,000 
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Table 2: Primary Antibodies for Western Blotting   
 
 
 
 
 
 
Primary antibody target Supplier (catalog no.) Dilution 
Phospho (Ser16)- heat shock protein 20 (HSP20) Abcam (ab58522) 1:10,000 
Total heat shock protein 20 (HSP20) Abcam (ab184161) 1:80,000 
Connexin-43(Cx43) New England BioLabs (#3512) 1:1,000 
Oxytocin receptor (OTR) Santa Cruz (sc-8102) 1:1,000 
Cyclooxygenase-2 (COX-2) Santa Cruz (sc-1745) 1:1,000 
Calponin Abcam (ab46794) 1:20,000 
Sarco/endo-plasmic reticulum calcium ATPase 2 
(SERCA2) 
Abcam (ab2817) 1:1,000 
Smooth muscle myosin heavy chain (SM-MHC) Millipore (MAB3568) 1:10,000 
Phosphodiesterase 4B (PDE4B) Abcam (ab112014) 1:500 
Protein kinase A regulatory subunit 2α (PKA RIIα) Abcam (ab38949) 1:500 
G protein αs (Gαs) Abcam (ab83735) 1:4,000 
Phospho (Ser3)-cofilin  New England BioLabs (#3311) 1:500 
Total cofilin  New England BioLabs (#3312) 1:500 
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) 
Millipore (MAB374) 1:40,000 
β-tubulin  Abcam (ab21057) 1:1,000 
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Table 3: Primer sequences for qPCR  
Name of mRNA 
template 
Accession 
number 
Forward primer sequence  
(5’ to 3’) 
Reverse primer 
sequence  
(5’ to 3’) 
Amplicon 
size (bp) 
qPCR CT 
range 
PGE2 receptor subtype 1 
(PTGER1) 
NM_0009
55.2 
AACCAGATCCTGGACC
CTTG 
GGCCTCTGGTTGTGC
TTAGAA 
198 n/a 
PGE2 receptor subtype 2 
(PTGER2) 
NM_0009
56.3 
GCTCCTTGCCTTTCACG
ATTT 
AGGATGGCAAAGACC
CAAGG 
127 25.1-34.5 
PGE2 receptor subtype 3 
(PTGER3) 
NM_0011
26044.1 
ATGACTGTTTTCGGGCT
CTC 
GGCCACTGGACGGTG
TACT 
203 29.8-32.2 
PGE2 receptor subtype 4 
(PTGER4) 
NM_0009
58.2 
ACAGCCACTACGTGGA
CAAG 
ACAAGCACGTTGCAG
AGGAC 
238 n/a 
PGE synthase 1 
(PTGES) 
NM_0048
78.4 
GAAGAAGGCCTTTGCC
AACCC 
GTGCATCCAGGCGAC
AAAAG 
187 32.1-35.9 
PGE synthase 2 
(PTGES2) 
NM_0250
72.6 
GTGGAATCCCATCCCTG
GGT 
ATGACAGGCGCCACA
AACC 
100 31.9-33.4 
PGE synthase 3 
(PTGES3) 
NM_0066
01.6 
 
CGACCGGAGAGAAAAA
GCGG 
GCAGGCTGCATTGTG
AACGG 
122 24.3-27.2 
PGF2α receptor (PTGFR) 
1 
NM_0009
59.3 
TGGAGCCCATTTCTGGT
TACA 
TGCACTCCACAGCAT
TGACT 
194 24.7-39.4 
PGF2α receptor (PTGFR) 
2 
NM_0010
39585.1 
GTAATCCAGCTCCTGGC
GAT 
CAATGTTGGCCATTG
TAACCTATG 
147 n/a 
PGF2α synthase (PGFS) NM_0037
39.5 
ATTTGGCACCTATGCAC
CTC 
CACACTGCCATCTGC
AATCT 
163 30.5-33.4 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
(GAPDH) 
NM_0020
46.5 
TGATGACATCAAGAAG
GTGGTGAAG 
TCCTTGGAGGCCATG
TAGGCCAT 
240 19.3-30.7 
 
